Bromide

Bromide

SCHEMBL313835

CCCCCCCCCCCCCCCC[N+](C)(C)C(C)O.[Br-]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 12/20 0.52
ALDH1A1 P00352 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
ALOX12 P18054 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HIF1A Q16665 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HSP90AA1 P07900 1/20 0.48
RAD52 P43351 1/20 0.48
HTT P42858 1/20 0.48
SLC22A1 O15245 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL313595 1.00 DNM1 (0.52) DNM1ALDH1A1TP53CYP3A4ALOX15
Bromide SCHEMBL6289482 1.00 DNM1 (0.52) DNM1ALDH1A1TP53CYP3A4ALOX15
Bromide SCHEMBL727878 1.00 DNM1 (0.52) DNM1ALDH1A1TP53CYP3A4ALOX15
Bromide SCHEMBL27904226 1.00 DNM1 (0.52) DNM1ALDH1A1TP53CYP3A4ALOX15
Hydrochloric Acid SCHEMBL441666 0.98 DNM1 (0.50) DNM1ALDH1A1TP53CYP3A4ALOX15
SCHEMBL3282068 0.98 DNM1 (0.50) DNM1HSP90AA1RAD52HTTSLC22A1
SCHEMBL240163 0.98 DNM1 (0.50) DNM1HSP90AA1RAD52HTTSLC22A1
SCHEMBL4313259 0.98 DNM1 (0.50) DNM1HSP90AA1RAD52HTTSLC22A1
SCHEMBL238533 0.98 DNM1 (0.50) DNM1HSP90AA1RAD52HTTSLC22A1
SCHEMBL239715 0.98 DNM1 (0.50) DNM1HSP90AA1RAD52HTTSLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115160017-B Preparation method of high-strength open-cell zirconia foam ceramic 中国科学院上海硅酸盐研究所 2023-06-02 CN claimed
CN-115160017-A Preparation method of high-strength open-cell zirconia foamed ceramic 中国科学院上海硅酸盐研究所 2022-10-11 CN claimed
CN-111205093-A Preparation method of ultra-light silicon nitride foamed ceramic 中国科学院上海硅酸盐研究所 2020-05-29 CN claimed
EP-2411560-A1 PROCESS FOR SINTERING NANOPARTICLES AT LOW TEMPERATURES Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) 2012-02-01 EP claimed
WO-2010109465-A1 PROCESS FOR SINTERING NANOPARTICLES AT LOW TEMPERATURES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2010-09-30 WO claimed
WO-2001051767-A2 ADDITION OF SOLIDS TO GENERATE VISCOSITY DOWNHOLE SCHLUMBERGER TECHNOLOGY CORPORATION (US) 2001-07-19 WO claimed
US-20260042956-A1 METHOD FOR SINGLE-STAGE TREATMENT OF SILICEOUS SUBTERRANEAN FORMATIONS SCHLUMBERGER TECHNOLOGY CORPORATION 2026-02-12 US disclosed
CN-119320274-A Double-aperture distributed zirconia capillary core for loop heat pipe and preparation method thereof 中国科学院上海硅酸盐研究所 2025-01-17 CN disclosed
EP-2820093-B1 INKS CONTAINING METAL PRECURSORS NANOPARTICLES SINGAPORE ASAHI CHEMICAL & SOLDER IND PTE LTD (SG) 2024-09-18 EP disclosed
US-12054626-B2 Inks containing metal precursors nanoparticles SINGAPORE ASAHI CHEMICAL & SOLDER IND. PTE. LTD (SG) 2024-08-06 US disclosed
WO-2024026137-A1 METHOD FOR SINGLE-STAGE TREATMENT OF SILICEOUS SUBTERRANEAN FORMATIONS SCHLUMBERGER TECHNOLOGY CORPORATION (US) 2024-02-01 WO disclosed
CN-115160017-B Preparation method of high-strength open-cell zirconia foam ceramic 中国科学院上海硅酸盐研究所 2023-06-02 CN disclosed
CN-115160017-A Preparation method of high-strength open-cell zirconia foamed ceramic 中国科学院上海硅酸盐研究所 2022-10-11 CN disclosed
US-5979557-A Methods for limiting the inflow of formation water and for stimulating subterranean formations SCHLUMBERGER TECHNOLOGY CORPORATION (US) 1999-11-09 US disclosed
US-5964295-A FOR REDUCING FLUID LOSS DURING FRACTURING OF A FORMATION SCHLUMBERGER TECHNOLOGY CORPORATION, DOWELL DIVISION (US) 1999-10-12 US disclosed
EP-0835983-A2 Methods of fracturing subterranean formations SOFITECH N.V. (BE) 1998-04-15 EP disclosed
US-5551516-A VISCOELASTIC SURFACTANT BASED AQUEOUS FLUID SYSTEMS USING A QUATERNARY AMMONIUM HALIDE THICKENER DOWELL, A DIVISION OF SCHLUMBERGER TECHNOLOGY CORPORATION 1996-09-03 US disclosed
EP-0142028-B1 REVERSIBLE PHASE CHANGE COMPOSITION FOR STORING THERMAL ENERGY THE DOW CHEMICAL COMPANY (US) 1987-08-05 EP disclosed
US-4585572-A CATIONIC SURFACTANT THICKENER THE DOW CHEMICAL COMPANY (US) 1986-04-29 US disclosed
EP-0142028-A1 Reversible phase change composition for storing thermal energy THE DOW CHEMICAL COMPANY (US) 1985-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042956-A1 METHOD FOR SINGLE-STAGE TREATMENT OF SILICEOUS SUBTERRANEAN FORMATIONS YAP1, S100A10, FOXM1 DNM1 925/4885ALDH1A1 4656/4885TP53 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.